Diabetes Strategies for Primary Care-What's New in the Management of the Diabetic Kidney? A Pro/Con Debate

Video Transcription

Video Summary

The session was titled "What's New in the Management of Diabetic Kidney Disease" and featured two speakers, Dr. Catherine Tuttle and Dr. Robert Stanton. Dr. Tuttle's presentation focused on the risks and benefits of finaranone, while Dr. Stanton discussed other therapies. Dr. Tuttle emphasized the prevalence and risks of diabetes and chronic kidney disease, noting that kidney disease is a serious matter and the most common cause of chronic kidney disease and kidney failure worldwide. She highlighted that albuminuria screening is crucial for identifying high cardiovascular and kidney disease risk in patients with diabetes. Dr. Tuttle also discussed the breakthrough therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, which have shown efficacy in reducing kidney and cardiovascular risks in patients with diabetes and chronic kidney disease. Dr. Stanton provided an alternative viewpoint, expressing concerns about the long-term risks of pouring glucose down the nephron with SGLT2 inhibitors. He also questioned the interpretation of GFR as a reflection of nephron number and highlighted that hyperfiltration caused by these drugs may have unintended consequences. Despite his concerns, Dr. Stanton acknowledged the cardiovascular benefits of SGLT2 inhibitors and emphasized the importance of monitoring albuminuria and personalizing treatment approaches for patients. Overall, the session provided insights into the current and future management of diabetic kidney disease.

Keywords

Management of Diabetic Kidney Disease

Dr. Catherine Tuttle

Dr. Robert Stanton

Finaranone

Therapies for Diabetic Kidney Disease

Albuminuria Screening

SGLT2 Inhibitors

GLP-1 Receptor Agonists

Cardiovascular and Kidney Disease Risks